PDCD1 and cancer: Tumors with higher mutational loads, such as melanoma, NSCLC, and bladder cancer, have shown the greatest response rates to anti-PD-1/PD-L1 therapy, while cancers with relatively low mutation rates (pancreatic and prostate cancers) have shown low response to these therapies [51].